Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway

Dramatic advances in immune therapy have emerged as a promising strategy in cancer therapeutics. In addition to chemotherapy and radiotherapy, inhibitors targeting immune-checkpoint molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death receptor-1 (PD-1) and its ligand (P...

Descripción completa

Detalles Bibliográficos
Autores principales: Wakabayashi, Grace, Lee, Yu-Ching, Luh, Frank, Kuo, Chun-Nan, Chang, Wei-Chao, Yen, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894306/
https://www.ncbi.nlm.nih.gov/pubmed/31801525
http://dx.doi.org/10.1186/s12929-019-0588-8
_version_ 1783476365743357952
author Wakabayashi, Grace
Lee, Yu-Ching
Luh, Frank
Kuo, Chun-Nan
Chang, Wei-Chao
Yen, Yun
author_facet Wakabayashi, Grace
Lee, Yu-Ching
Luh, Frank
Kuo, Chun-Nan
Chang, Wei-Chao
Yen, Yun
author_sort Wakabayashi, Grace
collection PubMed
description Dramatic advances in immune therapy have emerged as a promising strategy in cancer therapeutics. In addition to chemotherapy and radiotherapy, inhibitors targeting immune-checkpoint molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) demonstrate impressive clinical benefits in clinical trials. In this review, we present background information about therapies involving PD-1/PD-L1 blockade and provide an overview of current clinical trials. Furthermore, we present recent advances involving predictive biomarkers associated with positive therapeutic outcomes in cancer immunotherapy.
format Online
Article
Text
id pubmed-6894306
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68943062019-12-11 Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway Wakabayashi, Grace Lee, Yu-Ching Luh, Frank Kuo, Chun-Nan Chang, Wei-Chao Yen, Yun J Biomed Sci Review Dramatic advances in immune therapy have emerged as a promising strategy in cancer therapeutics. In addition to chemotherapy and radiotherapy, inhibitors targeting immune-checkpoint molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) demonstrate impressive clinical benefits in clinical trials. In this review, we present background information about therapies involving PD-1/PD-L1 blockade and provide an overview of current clinical trials. Furthermore, we present recent advances involving predictive biomarkers associated with positive therapeutic outcomes in cancer immunotherapy. BioMed Central 2019-12-05 /pmc/articles/PMC6894306/ /pubmed/31801525 http://dx.doi.org/10.1186/s12929-019-0588-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Wakabayashi, Grace
Lee, Yu-Ching
Luh, Frank
Kuo, Chun-Nan
Chang, Wei-Chao
Yen, Yun
Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
title Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
title_full Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
title_fullStr Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
title_full_unstemmed Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
title_short Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
title_sort development and clinical applications of cancer immunotherapy against pd-1 signaling pathway
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894306/
https://www.ncbi.nlm.nih.gov/pubmed/31801525
http://dx.doi.org/10.1186/s12929-019-0588-8
work_keys_str_mv AT wakabayashigrace developmentandclinicalapplicationsofcancerimmunotherapyagainstpd1signalingpathway
AT leeyuching developmentandclinicalapplicationsofcancerimmunotherapyagainstpd1signalingpathway
AT luhfrank developmentandclinicalapplicationsofcancerimmunotherapyagainstpd1signalingpathway
AT kuochunnan developmentandclinicalapplicationsofcancerimmunotherapyagainstpd1signalingpathway
AT changweichao developmentandclinicalapplicationsofcancerimmunotherapyagainstpd1signalingpathway
AT yenyun developmentandclinicalapplicationsofcancerimmunotherapyagainstpd1signalingpathway

Ejemplares similares